SCHEMBL2264667

SCHEMBL2264667

CCOc1cnc(-c2cccc(C(=O)c3nn(-c4cnn(C)c4)ccc3=O)c2)nc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP2C9 P11712 1/20 0.36
FGFR3 P22607 2/20 0.36
KDR P35968 2/20 0.36
BRD4 O60885 1/20 0.35
CCL2 P13500 1/20 0.35
GAA P10253 1/20 0.35
FYN P06241 1/20 0.35
ALKBH1 Q13686 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
HSD17B13 Q7Z5P4 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13449435 0.94 POLB (0.40) POLBMEN1KMT2ACYP2C9FGFR3
SCHEMBL13449439 0.85 POLB (0.39) POLBMEN1KMT2ACYP2C9KDR
SCHEMBL13274645 0.84 NPC1 (0.33) POLBFGFR3KDRBRD4CCL2
SCHEMBL2221611 0.83 BRD4 (0.36) CYP2C9FGFR3KDRBRD4CCL2
SCHEMBL2224149 0.82 BRD4 (0.35) FGFR3KDRBRD4CCL2ALKBH1
SCHEMBL164227 0.82 BRD4 (0.37) FGFR3KDRBRD4CCL2FYN
SCHEMBL13274991 0.81 BRD4 (0.35) MEN1KMT2AFGFR3KDRBRD4
SCHEMBL2266777 0.80 MET (0.35) FGFR3KDRBRD4CCL2FGFR2
SCHEMBL2221640 0.80 MET (0.34) FGFR3KDRBRD4CCL2FGFR2
SCHEMBL13449340 0.80 BRD4 (0.34) FGFR3KDRBRD4CCL2ALKBH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 POLB 1954/4885MEN1 1349/4885KMT2A 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.